BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21445072)

  • 21. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
    Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
    Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies.
    Cole CB; Russler-Germain DA; Ketkar S; Verdoni AM; Smith AM; Bangert CV; Helton NM; Guo M; Klco JM; O'Laughlin S; Fronick C; Fulton R; Chang GS; Petti AA; Miller CA; Ley TJ
    J Clin Invest; 2017 Oct; 127(10):3657-3674. PubMed ID: 28872462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
    Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
    Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNMT3A in haematological malignancies.
    Yang L; Rau R; Goodell MA
    Nat Rev Cancer; 2015 Mar; 15(3):152-65. PubMed ID: 25693834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alterations to
    Venugopal K; Feng Y; Shabashvili D; Guryanova OA
    Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation.
    Bhogal B; Weir BA; Crescenzo R; Marien A; Kwon MC; Philippar U; Cowley GS
    Commun Biol; 2022 Nov; 5(1):1174. PubMed ID: 36329185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.
    Sanders MA; Chew E; Flensburg C; Zeilemaker A; Miller SE; Al Hinai AS; Bajel A; Luiken B; Rijken M; Mclennan T; Hoogenboezem RM; Kavelaars FG; Fröhling S; Blewitt ME; Bindels EM; Alexander WS; Löwenberg B; Roberts AW; Valk PJM; Majewski IJ
    Blood; 2018 Oct; 132(14):1526-1534. PubMed ID: 30049810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
    Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
    Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
    Abdel-Wahab O; Levine RL
    Blood; 2013 May; 121(18):3563-72. PubMed ID: 23640996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNMT3A mutations in acute myeloid leukemia.
    Ley TJ; Ding L; Walter MJ; McLellan MD; Lamprecht T; Larson DE; Kandoth C; Payton JE; Baty J; Welch J; Harris CC; Lichti CF; Townsend RR; Fulton RS; Dooling DJ; Koboldt DC; Schmidt H; Zhang Q; Osborne JR; Lin L; O'Laughlin M; McMichael JF; Delehaunty KD; McGrath SD; Fulton LA; Magrini VJ; Vickery TL; Hundal J; Cook LL; Conyers JJ; Swift GW; Reed JP; Alldredge PA; Wylie T; Walker J; Kalicki J; Watson MA; Heath S; Shannon WD; Varghese N; Nagarajan R; Westervelt P; Tomasson MH; Link DC; Graubert TA; DiPersio JF; Mardis ER; Wilson RK
    N Engl J Med; 2010 Dec; 363(25):2424-33. PubMed ID: 21067377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias.
    Yang L; Rodriguez B; Mayle A; Park HJ; Lin X; Luo M; Jeong M; Curry CV; Kim SB; Ruau D; Zhang X; Zhou T; Zhou M; Rebel VI; Challen GA; Gottgens B; Lee JS; Rau R; Li W; Goodell MA
    Cancer Cell; 2016 Jun; 29(6):922-934. PubMed ID: 27300438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
    Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
    Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic differentiation persists in human iPSCs defective in de novo DNA methylation.
    Cypris O; Franzen J; Frobel J; Glück P; Kuo CC; Schmitz S; Nüchtern S; Zenke M; Wagner W
    BMC Biol; 2022 Jun; 20(1):141. PubMed ID: 35705990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion.
    Tovy A; Reyes JM; Gundry MC; Brunetti L; Lee-Six H; Petljak M; Park HJ; Guzman AG; Rosas C; Jeffries AR; Baple E; Mill J; Crosby AH; Sency V; Xin B; Machado HE; Castillo D; Weitzel JN; Li W; Stratton MR; Campbell PJ; Wang H; Sanders MA; Goodell MA
    Cell Stem Cell; 2020 Aug; 27(2):326-335.e4. PubMed ID: 32673568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.
    Perugini M; Iarossi DG; Kok CH; Cummings N; Diakiw SM; Brown AL; Danner S; Bardy P; Bik To L; Wei AH; Lewis ID; D'Andrea RJ
    Leukemia; 2013 Jul; 27(7):1588-92. PubMed ID: 23187294
    [No Abstract]   [Full Text] [Related]  

  • 37. A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A
    Lu R; Wang J; Ren Z; Yin J; Wang Y; Cai L; Wang GG
    Cancer Res; 2019 Jul; 79(14):3583-3594. PubMed ID: 31164355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers.
    Kim MS; Kim YR; Yoo NJ; Lee SH
    APMIS; 2013 Feb; 121(2):85-94. PubMed ID: 23031157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.
    Kim SJ; Zhao H; Hardikar S; Singh AK; Goodell MA; Chen T
    Blood; 2013 Dec; 122(25):4086-9. PubMed ID: 24167195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome.
    Smith AM; LaValle TA; Shinawi M; Ramakrishnan SM; Abel HJ; Hill CA; Kirkland NM; Rettig MP; Helton NM; Heath SE; Ferraro F; Chen DY; Adak S; Semenkovich CF; Christian DL; Martin JR; Gabel HW; Miller CA; Ley TJ
    Nat Commun; 2021 Jul; 12(1):4549. PubMed ID: 34315901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.